Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
NCT00040638
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Non-small-cell Lung
Interventions
DRUG:
TLK286
Sponsor
Telik